Financial & competing interests disclosure
Paul de Souza is on the prostate advisory board of Amgen Australia Pty Ltd., and was previously on the prostate advisory board of Novartis Australia Pty Ltd. He has also received research funding from Novartis Australia Pty Ltd. Fred Saad serves on the advisory boards of, and has conducted research with, Novartis and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.